Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

Evommune

Status and phase: Completed; Phase 2

Conditions: Atopic Dermatitis Eczema

Treatments: Drug: EVO101

Study type: Interventional

Funder types: Industry

Identifiers

NCT05579899

EVO101-AD001

Details and patient eligibility

About

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

Full description

This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.

Enrollment: 119 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males or non-pregnant, non-lactating females, age 18 years or older
2. Chronic atopic dermatitis for at least 1 year
3. IGA score of 2 or 3
4. BSA of AD involvement of 4-12%
5. EASI of 5-20

Exclusion criteria

1. Significant AD flare with 4 weeks
2. Use of biologic therapy within 12 weeks
3. Regular use of tanning booth within 4 weeks
4. Skin condition that could interfere with study assessments

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

119 participants in 2 patient groups, including a placebo group

EVO101 Cream

Experimental group

Description:

Active Treatment, BID, 8 weeks

Treatment:

Drug: EVO101

Vehicle Cream

Placebo Comparator group

Description:

Vehicle Treatment, BID, 8 weeks

Treatment:

Drug: EVO101